Shattuck Labs (STTK) Stock Price, News & Analysis

Company Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on harnessing the power of commensal bacteria to develop novel therapeutics for chronic inflammatory and other immune-mediated diseases. The company’s proprietary platform engineers naturally occurring microbes to secrete therapeutic proteins directly at disease sites, offering a targeted approach designed to enhance safety and efficacy while minimizing systemic exposure. Shattuck Labs’ platform has been applied to multiple areas, including dermatology and oncology, reflecting the broad potential of microbe-based therapies.

The company’s lead candidate, STK-012, is currently in Phase 1/2 clinical trials for the treatment of moderate-to-severe atopic dermatitis. By leveraging a skin-resident bacterium engineered to produce anti-inflammatory molecules, STK-012 aims to reduce local inflammation and restore healthy barrier function. In addition to dermatology, Shattuck Labs is advancing preclinical programs in oncology and other specialty indications, positioning its platform to address a range of diseases that may benefit from localized biologic delivery.

Founded in 2015 and headquartered in Boulder, Colorado, Shattuck Labs was established on the principle that the human microbiome can be repurposed to treat complex diseases. Since its inception, the company has built a multidisciplinary team of microbiologists, immunologists and drug development experts. Shattuck Labs collaborates with academic centers and biopharmaceutical partners in North America and Europe to support its pipeline and explore new therapeutic applications.

Shattuck Labs is led by CEO Robert “Bob” Rosen, a veteran biopharmaceutical executive with experience commercializing specialty therapeutics. The company’s leadership team and board of directors include industry professionals with backgrounds in cell and gene therapy, clinical development and regulatory affairs. Together, they seek to advance Shattuck’s innovative microbial platform toward regulatory approval and global patient access.

Key Stats

• Today's Range: $0.81 to $0.84
• 50-Day Range: $0.77 to $1.19
• 52-Week Range: $0.69 to $4.99
• Volume: 67,248 shs
• Average Volume: 332,125 shs
• Market Capitalization: $39.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

Shattuck Labs Stock Analysis - MarketRank™

Shattuck Labs scored higher than 74% of companies evaluated by MarketBeat, and ranked 272nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Shattuck Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Shattuck Labs has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Shattuck Labs are expected to grow in the coming year, from ($1.48) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Shattuck Labs is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shattuck Labs is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Shattuck Labs has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.85% of the float of Shattuck Labs has been sold short.

Short Interest Ratio / Days to Cover

Shattuck Labs has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shattuck Labs has recently decreased by 51.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Shattuck Labs does not currently pay a dividend.

Dividend Growth

Shattuck Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.85% of the float of Shattuck Labs has been sold short.

Short Interest Ratio / Days to Cover

Shattuck Labs has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shattuck Labs has recently decreased by 51.92%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Shattuck Labs has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Shattuck Labs this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Shattuck Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shattuck Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.00% of the stock of Shattuck Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.74% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STTK Stock Analysis - Frequently Asked Questions

How have STTK shares performed this year?

Shattuck Labs' stock was trading at $1.21 on January 1st, 2025. Since then, STTK stock has decreased by 32.2% and is now trading at $0.82.

How were Shattuck Labs' earnings last quarter?

Shattuck Labs, Inc. (NASDAQ:STTK) posted its earnings results on Thursday, May, 1st. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.02.

When did Shattuck Labs IPO?

Shattuck Labs (STTK) raised $150 million in an initial public offering on Friday, October 9th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager.

How do I buy shares of Shattuck Labs?

Shares of STTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Shattuck Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shattuck Labs investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STTK
• CIK: 1680367
• Web: www.shattucklabs.com
• Phone: 512-900-4690
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Shattuck Labs: $7.50
• High Price Target: $16.00
• Low Price Target: $2.00
• Potential Upside/Downside: +814.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.41 million
• Net Margins: N/A
• Pretax Margin: -1,532.96%
• Return on Equity: -79.69%
• Return on Assets: -69.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.08
• Quick Ratio: 9.08

Sales & Book Value

• Annual Sales: $5.72 million
• Price / Sales: 6.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 47,900,000
• Free Float: 42,151,000
• Market Cap: $39.28 million
• Optionable: Optionable
• Beta: 1.63